Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. [electronic resource]
Producer: 20110203Description: 368 p. digitalISSN:- 1471-2407
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
- Biomarkers, Tumor -- metabolism
- ErbB Receptors -- antagonists & inhibitors
- Erlotinib Hydrochloride
- Everolimus
- Female
- Fluorescent Antibody Technique
- Humans
- Immunoenzyme Techniques
- Immunosuppressive Agents -- therapeutic use
- Male
- Middle Aged
- Neoplasm Staging
- Pancreatic Neoplasms -- drug therapy
- Phosphorylation
- Prognosis
- Prospective Studies
- Protein Kinase Inhibitors -- therapeutic use
- Proto-Oncogene Proteins c-akt -- metabolism
- Quinazolines -- therapeutic use
- Signal Transduction
- Sirolimus -- analogs & derivatives
- Survival Rate
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.